Expanding the genetic basis of copy number variation in familial breast cancer

Familial breast cancer (fBC) is generally associated with an early age of diagnosis and a higher frequency of disease among family members. Over the past two decades a number of genes have been identified that are unequivocally associated with breast cancer (BC) risk but there remain a significant p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hereditary cancer in clinical practice 2014-05, Vol.12 (1), p.15-15, Article 15
Hauptverfasser: Masson, Amy L, Talseth-Palmer, Bente A, Evans, Tiffany-Jane, Grice, Desma M, Hannan, Garry N, Scott, Rodney J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 15
container_issue 1
container_start_page 15
container_title Hereditary cancer in clinical practice
container_volume 12
creator Masson, Amy L
Talseth-Palmer, Bente A
Evans, Tiffany-Jane
Grice, Desma M
Hannan, Garry N
Scott, Rodney J
description Familial breast cancer (fBC) is generally associated with an early age of diagnosis and a higher frequency of disease among family members. Over the past two decades a number of genes have been identified that are unequivocally associated with breast cancer (BC) risk but there remain a significant proportion of families that cannot be accounted for by these genes. Copy number variants (CNVs) are a form of genetic variation yet to be fully explored for their contribution to fBC. CNVs exert their effects by either being associated with whole or partial gene deletions or duplications and by interrupting epigenetic patterning thereby contributing to disease development. CNV analysis can also be used to identify new genes and loci which may be associated with disease risk. The Affymetrix Cytogenetic Whole Genome 2.7 M (Cyto2.7 M) arrays were used to detect regions of genomic re-arrangement in a cohort of 129 fBC BRCA1/BRCA2 mutation negative patients with a young age of diagnosis (55 years of age). CNV analysis revealed the presence of 275 unique rearrangements that were not present in the control population suggestive of their involvement in BC risk. Several CNVs were found that have been previously reported as BC susceptibility genes. This included CNVs in RPA3, NBN (NBS1), MRE11A and CYP19A1 in five unrelated fBC patients suggesting that these genes are involved in BC initiation and/or progression. Of special interest was the identification of WWOX and FHIT rearrangements in three unrelated fBC patients. This study has identified a number of CNVs that potentially contribute to BC initiation and/or progression. The identification of CNVs that are associated with known tumour suppressor genes is of special interest that warrants further larger studies to understand their precise role in fBC.
doi_str_mv 10.1186/1897-4287-12-15
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4064283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A540666944</galeid><sourcerecordid>A540666944</sourcerecordid><originalsourceid>FETCH-LOGICAL-b785t-fd95b4d359e9a07e31b3e98839d49a6b1c93270367d0bb06282381050083b3a23</originalsourceid><addsrcrecordid>eNqNksuLFDEQxhtR3IeevUlAkL30bp7dyUVYl_UBi170HJJ09UyW7mRMuhf3vzfNrOOOjCA5JFT98lH1VVXVK4LPCZHNBZGqrTmVbU1oTcST6ngXeVreLSM1ZZgeVSc532IsmGzV8-qIciUE4c1x9eX658aEzocVmtaAVhBg8g5Zk31GsUcubu5RmEcLCd2Z5M3kY0A-oN6MfvBmQDaByRNyJjhIL6pnvRkyvHy4T6vvH66_XX2qb75-_Hx1eVPbVoqp7jslLO-YUKAMboERy0BJyVTHlWkscYrRFrOm7bC1uKGSMkmwwFgyywxlp9W7re5mtiN0DsKUzKA3yY8m3etovN7PBL_Wq3inOW6KOawIvN8KWB__IbCfcXHUi7d68VYTqokoImcPVaT4Y4Y86dFnB8NgAsQ5F4RzTJgi-D9QplpSRrKU9uYv9DbOKRQ7F0pKxRVp_lArM4D2oY-lTLeI6ktRumwaxXmh6gPUMuXSUwzQ-xLe488P8OV0MHp38MPbRx_WYIZpneMwL2uS98GLLehSzDlBv_OaYL3s8gF3Xz-e8Y7_vbzsF8Md6zA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1538894916</pqid></control><display><type>article</type><title>Expanding the genetic basis of copy number variation in familial breast cancer</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Masson, Amy L ; Talseth-Palmer, Bente A ; Evans, Tiffany-Jane ; Grice, Desma M ; Hannan, Garry N ; Scott, Rodney J</creator><creatorcontrib>Masson, Amy L ; Talseth-Palmer, Bente A ; Evans, Tiffany-Jane ; Grice, Desma M ; Hannan, Garry N ; Scott, Rodney J</creatorcontrib><description>Familial breast cancer (fBC) is generally associated with an early age of diagnosis and a higher frequency of disease among family members. Over the past two decades a number of genes have been identified that are unequivocally associated with breast cancer (BC) risk but there remain a significant proportion of families that cannot be accounted for by these genes. Copy number variants (CNVs) are a form of genetic variation yet to be fully explored for their contribution to fBC. CNVs exert their effects by either being associated with whole or partial gene deletions or duplications and by interrupting epigenetic patterning thereby contributing to disease development. CNV analysis can also be used to identify new genes and loci which may be associated with disease risk. The Affymetrix Cytogenetic Whole Genome 2.7 M (Cyto2.7 M) arrays were used to detect regions of genomic re-arrangement in a cohort of 129 fBC BRCA1/BRCA2 mutation negative patients with a young age of diagnosis (&lt;50 years) compared to 40 unaffected healthy controls (&gt;55 years of age). CNV analysis revealed the presence of 275 unique rearrangements that were not present in the control population suggestive of their involvement in BC risk. Several CNVs were found that have been previously reported as BC susceptibility genes. This included CNVs in RPA3, NBN (NBS1), MRE11A and CYP19A1 in five unrelated fBC patients suggesting that these genes are involved in BC initiation and/or progression. Of special interest was the identification of WWOX and FHIT rearrangements in three unrelated fBC patients. This study has identified a number of CNVs that potentially contribute to BC initiation and/or progression. The identification of CNVs that are associated with known tumour suppressor genes is of special interest that warrants further larger studies to understand their precise role in fBC.</description><identifier>ISSN: 1731-2302</identifier><identifier>ISSN: 1897-4287</identifier><identifier>EISSN: 1897-4287</identifier><identifier>DOI: 10.1186/1897-4287-12-15</identifier><identifier>PMID: 24955146</identifier><language>eng</language><publisher>Poland: BioMed Central Ltd</publisher><subject>Analysis ; Breast cancer ; Chromosomes ; Deoxyribonucleic acid ; Development and progression ; Disease susceptibility ; DNA ; DNA methylation ; Epidemiology ; Epigenetic inheritance ; Epigenetics ; Gene loci ; Genes ; Genetic aspects ; Genetic research ; Genetic testing ; Genomes ; Genomics ; Health aspects ; Mutation ; Patients ; Quality control ; Risk assessment ; Studies</subject><ispartof>Hereditary cancer in clinical practice, 2014-05, Vol.12 (1), p.15-15, Article 15</ispartof><rights>COPYRIGHT 2014 BioMed Central Ltd.</rights><rights>2014 Masson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</rights><rights>Copyright © 2014 Masson et al.; licensee BioMed Central Ltd. 2014 Masson et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b785t-fd95b4d359e9a07e31b3e98839d49a6b1c93270367d0bb06282381050083b3a23</citedby><cites>FETCH-LOGICAL-b785t-fd95b4d359e9a07e31b3e98839d49a6b1c93270367d0bb06282381050083b3a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064283/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064283/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24955146$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Masson, Amy L</creatorcontrib><creatorcontrib>Talseth-Palmer, Bente A</creatorcontrib><creatorcontrib>Evans, Tiffany-Jane</creatorcontrib><creatorcontrib>Grice, Desma M</creatorcontrib><creatorcontrib>Hannan, Garry N</creatorcontrib><creatorcontrib>Scott, Rodney J</creatorcontrib><title>Expanding the genetic basis of copy number variation in familial breast cancer</title><title>Hereditary cancer in clinical practice</title><addtitle>Hered Cancer Clin Pract</addtitle><description>Familial breast cancer (fBC) is generally associated with an early age of diagnosis and a higher frequency of disease among family members. Over the past two decades a number of genes have been identified that are unequivocally associated with breast cancer (BC) risk but there remain a significant proportion of families that cannot be accounted for by these genes. Copy number variants (CNVs) are a form of genetic variation yet to be fully explored for their contribution to fBC. CNVs exert their effects by either being associated with whole or partial gene deletions or duplications and by interrupting epigenetic patterning thereby contributing to disease development. CNV analysis can also be used to identify new genes and loci which may be associated with disease risk. The Affymetrix Cytogenetic Whole Genome 2.7 M (Cyto2.7 M) arrays were used to detect regions of genomic re-arrangement in a cohort of 129 fBC BRCA1/BRCA2 mutation negative patients with a young age of diagnosis (&lt;50 years) compared to 40 unaffected healthy controls (&gt;55 years of age). CNV analysis revealed the presence of 275 unique rearrangements that were not present in the control population suggestive of their involvement in BC risk. Several CNVs were found that have been previously reported as BC susceptibility genes. This included CNVs in RPA3, NBN (NBS1), MRE11A and CYP19A1 in five unrelated fBC patients suggesting that these genes are involved in BC initiation and/or progression. Of special interest was the identification of WWOX and FHIT rearrangements in three unrelated fBC patients. This study has identified a number of CNVs that potentially contribute to BC initiation and/or progression. The identification of CNVs that are associated with known tumour suppressor genes is of special interest that warrants further larger studies to understand their precise role in fBC.</description><subject>Analysis</subject><subject>Breast cancer</subject><subject>Chromosomes</subject><subject>Deoxyribonucleic acid</subject><subject>Development and progression</subject><subject>Disease susceptibility</subject><subject>DNA</subject><subject>DNA methylation</subject><subject>Epidemiology</subject><subject>Epigenetic inheritance</subject><subject>Epigenetics</subject><subject>Gene loci</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Genetic research</subject><subject>Genetic testing</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Health aspects</subject><subject>Mutation</subject><subject>Patients</subject><subject>Quality control</subject><subject>Risk assessment</subject><subject>Studies</subject><issn>1731-2302</issn><issn>1897-4287</issn><issn>1897-4287</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNksuLFDEQxhtR3IeevUlAkL30bp7dyUVYl_UBi170HJJ09UyW7mRMuhf3vzfNrOOOjCA5JFT98lH1VVXVK4LPCZHNBZGqrTmVbU1oTcST6ngXeVreLSM1ZZgeVSc532IsmGzV8-qIciUE4c1x9eX658aEzocVmtaAVhBg8g5Zk31GsUcubu5RmEcLCd2Z5M3kY0A-oN6MfvBmQDaByRNyJjhIL6pnvRkyvHy4T6vvH66_XX2qb75-_Hx1eVPbVoqp7jslLO-YUKAMboERy0BJyVTHlWkscYrRFrOm7bC1uKGSMkmwwFgyywxlp9W7re5mtiN0DsKUzKA3yY8m3etovN7PBL_Wq3inOW6KOawIvN8KWB__IbCfcXHUi7d68VYTqokoImcPVaT4Y4Y86dFnB8NgAsQ5F4RzTJgi-D9QplpSRrKU9uYv9DbOKRQ7F0pKxRVp_lArM4D2oY-lTLeI6ktRumwaxXmh6gPUMuXSUwzQ-xLe488P8OV0MHp38MPbRx_WYIZpneMwL2uS98GLLehSzDlBv_OaYL3s8gF3Xz-e8Y7_vbzsF8Md6zA</recordid><startdate>20140524</startdate><enddate>20140524</enddate><creator>Masson, Amy L</creator><creator>Talseth-Palmer, Bente A</creator><creator>Evans, Tiffany-Jane</creator><creator>Grice, Desma M</creator><creator>Hannan, Garry N</creator><creator>Scott, Rodney J</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140524</creationdate><title>Expanding the genetic basis of copy number variation in familial breast cancer</title><author>Masson, Amy L ; Talseth-Palmer, Bente A ; Evans, Tiffany-Jane ; Grice, Desma M ; Hannan, Garry N ; Scott, Rodney J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b785t-fd95b4d359e9a07e31b3e98839d49a6b1c93270367d0bb06282381050083b3a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Analysis</topic><topic>Breast cancer</topic><topic>Chromosomes</topic><topic>Deoxyribonucleic acid</topic><topic>Development and progression</topic><topic>Disease susceptibility</topic><topic>DNA</topic><topic>DNA methylation</topic><topic>Epidemiology</topic><topic>Epigenetic inheritance</topic><topic>Epigenetics</topic><topic>Gene loci</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Genetic research</topic><topic>Genetic testing</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Health aspects</topic><topic>Mutation</topic><topic>Patients</topic><topic>Quality control</topic><topic>Risk assessment</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masson, Amy L</creatorcontrib><creatorcontrib>Talseth-Palmer, Bente A</creatorcontrib><creatorcontrib>Evans, Tiffany-Jane</creatorcontrib><creatorcontrib>Grice, Desma M</creatorcontrib><creatorcontrib>Hannan, Garry N</creatorcontrib><creatorcontrib>Scott, Rodney J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hereditary cancer in clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masson, Amy L</au><au>Talseth-Palmer, Bente A</au><au>Evans, Tiffany-Jane</au><au>Grice, Desma M</au><au>Hannan, Garry N</au><au>Scott, Rodney J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expanding the genetic basis of copy number variation in familial breast cancer</atitle><jtitle>Hereditary cancer in clinical practice</jtitle><addtitle>Hered Cancer Clin Pract</addtitle><date>2014-05-24</date><risdate>2014</risdate><volume>12</volume><issue>1</issue><spage>15</spage><epage>15</epage><pages>15-15</pages><artnum>15</artnum><issn>1731-2302</issn><issn>1897-4287</issn><eissn>1897-4287</eissn><abstract>Familial breast cancer (fBC) is generally associated with an early age of diagnosis and a higher frequency of disease among family members. Over the past two decades a number of genes have been identified that are unequivocally associated with breast cancer (BC) risk but there remain a significant proportion of families that cannot be accounted for by these genes. Copy number variants (CNVs) are a form of genetic variation yet to be fully explored for their contribution to fBC. CNVs exert their effects by either being associated with whole or partial gene deletions or duplications and by interrupting epigenetic patterning thereby contributing to disease development. CNV analysis can also be used to identify new genes and loci which may be associated with disease risk. The Affymetrix Cytogenetic Whole Genome 2.7 M (Cyto2.7 M) arrays were used to detect regions of genomic re-arrangement in a cohort of 129 fBC BRCA1/BRCA2 mutation negative patients with a young age of diagnosis (&lt;50 years) compared to 40 unaffected healthy controls (&gt;55 years of age). CNV analysis revealed the presence of 275 unique rearrangements that were not present in the control population suggestive of their involvement in BC risk. Several CNVs were found that have been previously reported as BC susceptibility genes. This included CNVs in RPA3, NBN (NBS1), MRE11A and CYP19A1 in five unrelated fBC patients suggesting that these genes are involved in BC initiation and/or progression. Of special interest was the identification of WWOX and FHIT rearrangements in three unrelated fBC patients. This study has identified a number of CNVs that potentially contribute to BC initiation and/or progression. The identification of CNVs that are associated with known tumour suppressor genes is of special interest that warrants further larger studies to understand their precise role in fBC.</abstract><cop>Poland</cop><pub>BioMed Central Ltd</pub><pmid>24955146</pmid><doi>10.1186/1897-4287-12-15</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1731-2302
ispartof Hereditary cancer in clinical practice, 2014-05, Vol.12 (1), p.15-15, Article 15
issn 1731-2302
1897-4287
1897-4287
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4064283
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings
subjects Analysis
Breast cancer
Chromosomes
Deoxyribonucleic acid
Development and progression
Disease susceptibility
DNA
DNA methylation
Epidemiology
Epigenetic inheritance
Epigenetics
Gene loci
Genes
Genetic aspects
Genetic research
Genetic testing
Genomes
Genomics
Health aspects
Mutation
Patients
Quality control
Risk assessment
Studies
title Expanding the genetic basis of copy number variation in familial breast cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T05%3A05%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expanding%20the%20genetic%20basis%20of%20copy%20number%20variation%20in%20familial%20breast%20cancer&rft.jtitle=Hereditary%20cancer%20in%20clinical%20practice&rft.au=Masson,%20Amy%20L&rft.date=2014-05-24&rft.volume=12&rft.issue=1&rft.spage=15&rft.epage=15&rft.pages=15-15&rft.artnum=15&rft.issn=1731-2302&rft.eissn=1897-4287&rft_id=info:doi/10.1186/1897-4287-12-15&rft_dat=%3Cgale_pubme%3EA540666944%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1538894916&rft_id=info:pmid/24955146&rft_galeid=A540666944&rfr_iscdi=true